Open innovation

By delivering research-based cutting-edge image analysis solutions to partners across the globe,
we aim to serve as an open hub for innovation—driving scientific advancement,
enhancing healthcare, and contributing to the well-being of society.

Partners

For inquiries regarding collaboration and joint research

Joint Research & Development

LPIXEL provides image analysis solutions to pharmaceutical companies and medical device manufacturers,
including expertise in the development and commercialisation of imaging-based SaMD.

OPEN INNOVATION #01

LPIXEL × OLYMPUS

Development of an AI-based landmarking and guidance system to support laparoscopic cholecystectomy in collaboration with OLYMPUS

LPIXEL has signed a joint business agreement with OLYMPUS corporation for the development and commercialization of an AI-based landmarking and guidance system for lapraoscopic cholecystectomy

LPIXEL has signed a joint business agreement with OLYMPUS corporation for the development and commercialization of an AI-based landmarking and guidance system for lapraoscopic cholecystectomy
Laparoscopic surgery faces challenges in ensuring consistent surgical outcomes across surgeons and institutions in Japan due to a shortage of surgeons in addition to the high requirement for both advanced equipment and highly skilled medical professionals.
Each year, approximately 120,000 laparoscopic cholecystectomies are performed in Japan. However, serious complications such as biliary injuries—caused by accidental bile duct damage near the gallbladder—occur in around 600 cases annually. A primary factor contributing to these injuries is the misidentification of anatomical structures by the surgeon.

During laparoscopic cholecystectomy, key anatomical landmarks (e.g., Landmark A to D) used to guide the area for resection will be segmented and displayed on a monitor in real time. The system will also feature an on/off toggle for landmark visibility and provide timely warnings at critical moments, supporting the surgeon’s decision-making process. This product is not yet approved under the Pharmaceuticals and Medical Devices Act.

OPEN INNOVATION #02

LPIXEL × Daiichi Sankyo

Comprehensive partnership with Daiichi Sankyo Co., Ltd. for the implementation of image AI analysis.

2022/07/20

Comprehensive partnership at the company-wide level
Discovering latent needs for AI application
All stages of the drug discovery value chain, including research, development, and manufacturing, are covered.

Excerpt from the July 2022 press release by Daiichi Sankyo
Through our joint research with LPIXEL, we have highly evaluated the company’s AI image analysis technology. To identify future needs and potential applications for AI image analysis, we have signed a basic agreement for a company-wide comprehensive partnership with LPIXEL.
Under this partnership, we will receive comprehensive technical support from LPIXEL for AI image analysis across the entire value chain—not only in research but also in development and manufacturing, where the use of AI image analysis technology is expected to be beneficial.
By making latent digital transformation (DX) needs more tangible, we aim to transform and accelerate various business processes toward the creation of innovative pharmaceuticals, including the application of new modalities such as gene therapy. Our ultimate goal is to deliver medicines to patients as quickly as possible.

OPEN INNOVATION #03

LPIXEL × etc.

Over 100 collaborative research products with industry and academia

Medical device manufacturers: Integrating AI into medical devices
Biopharmaceutical Companies: AI image analysis for drug discovery, pre-clinical trials, CMC, and application of AI to diagnostic technology for clinical trials and post-marketing surveillance

Takeda Pharmaceutical Company Limited
Astellas Pharma Inc.
TAIHO PHARMACEUTICAL CO., LTD.
Chugai Pharmaceutical Co., Ltd.
Kyowa Kirin Co., Ltd.
Shionogi TechnoAdvance Research CO., LTD.
Maruho Co., Ltd.
ASAHI KASEI PHARMA CORPORATION

Global pharmaceutical company (company name undisclosed)
Olympus Corporation
TORAY INDUSTRIES, INC.
TORAY ENGINEERING Co.,Ltd.
National Center for Child Health and Development
National Institutes for Quantum Science and Technology
The University of Tokyo Hospital

This is a partial list, including only public organizations that have granted publication permission.

For inquiries regarding collaboration and joint research

The ‘EIRL’ platform simplifies the adoption of medical AI by allowing partner developers to seamlessly integrate their applications, making them readily accessible to healthcare institutions. leveraging LPIXEL’s end-to-end expertise—from product planning and data collection to development, regulatory affairs and sales—we provide comprehensive support including application integration, development systems, and regulatory approval support.